Thromboembolism and stroke Circulatory System Stroke
Conditions
Interventions
A three-year randomised controlled trial (RCT) will be conducted. All patients registering at the PMAS with a first prescription of warfarin for a minimum of six months and who agree to participate (n
Sponsors
Cité de la Santé de Laval (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient is referred to the Pharmacy Managed Anticoagulation Service (PMAS) with a prescription of warfarin for at least six months 2. The patient is aged 18 years and older, either sex 3. The patient agrees to go to the Cité de la Santé de Laval, the Centre Hospitalier Ambulatoire Régional de Laval, or one of the four Laval Centre Local de Services Communautaire for blood drawing during participation in the study (six months) 4. The patient lives in the Laval area 5. The patient is able to read and speak French or English 6. The patient agrees to participate in the study and has signed the informed consent form 7. The patient's treating physician has agreed to participate and has signed the informed consent form 8. It is expected that the patient will be transferred to the treating physician
Exclusion criteria
Exclusion criteria: 1. The patient participates to another study 2. The patient is referred to the PMAS for a pre-admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of time spent within the target INR range. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence and severity of major thromboembolic and haemorrhagic events 2. Health-related quality of life 3. Direct medical-care costs | — |
Countries
Canada
Outcome results
None listed